Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 8.51% | -14.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 8.51% | -14.48% | |||
| Cost of Revenue | 9.61% | -12.39% | |||
| Gross Profit | 7.86% | -15.69% | |||
| SG&A Expenses | -3.84% | 2.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.59% | -2.65% | |||
| Operating Income | 57.10% | -12,639.47% | |||
| Income Before Tax | 32.33% | -174.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.33% | -174.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.33% | -174.58% | |||
| EBIT | 57.10% | -12,639.47% | |||
| EBITDA | 62.42% | -836.70% | |||
| EPS Basic | 32.71% | -172.61% | |||
| Normalized Basic EPS | 32.58% | -217.86% | |||
| EPS Diluted | 29.91% | -172.61% | |||
| Normalized Diluted EPS | 32.58% | -217.86% | |||
| Average Basic Shares Outstanding | 0.36% | 0.86% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||